Abivax (AAVXF) Other financing activities (2024 - 2025)
Abivax (AAVXF) posted Other financing activities of $348.9 million for Q4 2025, up 616289.16% on a QoQ basis from $56598.0 in Q2 2025, and up 33.39% year-over-year from $261.5 million in Q4 2024.
Powered by 
Analysis
Abivax (AAVXF) Other financing activities (2024 - 2025) Analysis & Trends
Abivax has reported Other financing activities for 2 years, with the latest figure at $348.9 million in Q4 2025.
- On a quarterly basis, Other financing activities rose 33.39% year-over-year to $348.9 million in Q4 2025; TTM through Mar 2026 was $348.9 million, a 33.14% increase from a year earlier, with the FY2025 full-year figure at $349.2 million, up 33.39% from the prior year.
- Other financing activities was $348.9 million for Q4 2025 at Abivax, up from $56598.0 in the prior quarter.
- The five-year high for Other financing activities was $348.9 million in Q4 2025, with the low at $1098.2 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 210.98 Bn | 196.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.24 Bn | 178.06 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.38 Bn | 124.53 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.97 Bn | 74.97 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.80 Bn | 49.67 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.09 Bn | 30.78 Bn | 992.69 Mn |
| 8 | Biogen | 31.34 Bn | 30.05 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.11 Bn | 30.11 Bn | 1.16 Mn |
| 10 | Abivax | 10.92 Bn | 10.92 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 348.86 Mn |
| Jun 30, 2025 | 56,597.98 |
| Mar 31, 2025 | 262,971.11 |
| Dec 31, 2024 | 261.54 Mn |
| Sep 30, 2024 | 1,098.22 |
| Jun 30, 2024 | 259,529.91 |
| Mar 31, 2024 | 3,259.09 |